Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle L O'Donoghue

Showing results (1-10 of 118) with videos related to

Pageof 12
Sort By:
Nature Reviews. Cardiology|January 15, 2014
Acute coronary syndromes: targeting inflammation-what has the VISTA-16 trial taught us?Michelle L O'Donoghue
Cardiology and Therapy|August 20, 2014
Lp-PLA2 Inhibitors for the Reduction of Cardiovascular EventsDylan L Steen, Michelle L O'Donoghue
Circulation|June 20, 2020
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y<sub>12</sub> Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-AnalysisMichelle L O'Donoghue, Sabina A Murphy, Marc S Sabatine
Clinical Chemistry|November 21, 2013
Biomarkers in ACS and heart failure: should men and women be interpreted differently?Shweta R Motiwala, Amy Sarma, James L Januzzi, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|March 31, 2022
Antiplatelet therapy after percutaneous coronary interventionDominick J Angiolillo, Mattia Galli, Jean-Philippe Collet, et al.
Nature Medicine|December 7, 2021
Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trialChristian T Ruff, Michelle Baron, KyungAh Im, et al.
European Journal of Preventive Cardiology|March 15, 2018
Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndromeIlaria Cavallari, Christopher P Cannon, Eugene Braunwald, et al.
Journal of Thrombosis and Thrombolysis|December 5, 2018
Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal functionSimon Correa, Marc P Bonaca, Benjamin M Scirica, et al.
American Heart Journal|May 19, 2022
Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)Michelle L O'Donoghue, J Antonio G López, Beat Knusel, et al.
Journal of the American College of Cardiology|December 4, 2014
Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trialMarc P Bonaca, Benjamin M Scirica, Eugene Braunwald, et al.
Pageof 12

Showing results (1-10 of 118) with videos related to

Sort By:
Pageof 12
Nature Reviews. Cardiology|January 15, 2014
Acute coronary syndromes: targeting inflammation-what has the VISTA-16 trial taught us?Michelle L O'Donoghue
Cardiology and Therapy|August 20, 2014
Lp-PLA2 Inhibitors for the Reduction of Cardiovascular EventsDylan L Steen, Michelle L O'Donoghue
Circulation|June 20, 2020
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y<sub>12</sub> Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-AnalysisMichelle L O'Donoghue, Sabina A Murphy, Marc S Sabatine
Clinical Chemistry|November 21, 2013
Biomarkers in ACS and heart failure: should men and women be interpreted differently?Shweta R Motiwala, Amy Sarma, James L Januzzi, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|March 31, 2022
Antiplatelet therapy after percutaneous coronary interventionDominick J Angiolillo, Mattia Galli, Jean-Philippe Collet, et al.
Nature Medicine|December 7, 2021
Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trialChristian T Ruff, Michelle Baron, KyungAh Im, et al.
European Journal of Preventive Cardiology|March 15, 2018
Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndromeIlaria Cavallari, Christopher P Cannon, Eugene Braunwald, et al.
Journal of Thrombosis and Thrombolysis|December 5, 2018
Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal functionSimon Correa, Marc P Bonaca, Benjamin M Scirica, et al.
American Heart Journal|May 19, 2022
Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)Michelle L O'Donoghue, J Antonio G López, Beat Knusel, et al.
Journal of the American College of Cardiology|December 4, 2014
Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trialMarc P Bonaca, Benjamin M Scirica, Eugene Braunwald, et al.
Pageof 12